Barclays
COLL icon

Barclays’s Collegium Pharmaceutical COLL Stock Holding History

Barclays’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-9,000
Closed -$155K – 7041
2018
Q4 		$155K Sell
9,000
-129,400
-93% -$2.21M ﹤0.01% 4757
2018
Q3 		$2.04M Buy
+138,400
New +$2.45M ﹤0.01% 2856

Other funds holding COLL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Barclays's COLL Position: Q2 2026 in Review

Barclays increased its Collegium Pharmaceutical (COLL) stake by 50% in Q2 2026, buying an estimated $1.22M and bringing the position to 107,670 shares worth $3.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1972.

Barclays first reported a position in COLL in Q2 2015 and has held it in 45 quarters since. The position peaked at $4.8M in Q4 2025. 279 funds tracked by Wall St. Rank hold COLL as of Q2 2026.

  • Barclays held 107,670 shares of Collegium Pharmaceutical worth $3.9M as of Q2 2026.
  • Barclays bought 35,721 Collegium Pharmaceutical shares in Q2 2026, an estimated $1.22M.
  • Collegium Pharmaceutical made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1972 holding.
  • Barclays first reported a position in Collegium Pharmaceutical in Q2 2015 and has held it in 45 quarters since.
  • Barclays's Collegium Pharmaceutical position peaked at $4.8M in Q4 2025.
  • 279 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.